Condition

Dyskinesia

ClinicalTrials.gov condition label

Clinical trials12

Recruiting0

Common interventions10

Lead sponsors shown7

Clinical trials

12 shown

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease PatientsNCT02439125 · 2015-05-01

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaNCT02274766 · 2014-10-01

Open-Label Safety Study of ADS-5102 in PD Patients With LIDNCT02202551 · 2014-07-01

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)NCT02136914 · 2014-05-01

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease PatientsNCT01767129 · 2013-10-16

Capturing Parkinson's Disease Medication Side Effects During Daily ActivitiesNCT01429207 · 2011-08-01

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)NCT01397422 · 2011-07-01

Famotidine for Levodopa-induced Dyskinesia in PDNCT01937078 · 2011-04-01

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaNCT00105508 · 2004-09-30

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaNCT00105521 · 2004-09-30

Ethyl-Eicosapentaenoic Acid and Tardive DyskinesiaNCT00114595 · 2003-04-01

Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaNCT00314288 · 2002-07-01

Common interventions

PlaceboDRUG4 ADS-5102DRUG3 PlaceboOTHER2 SarizotanDRUG2 ADS-5102 (extended release amantadine HCl)DRUG1 AVP-923-45DRUG1 eicosapentaenoic acidDRUG1 Eltoprazine HClDRUG1 FamotidineDRUG1 Sarizotan HClDRUG1

Leading sponsors

Adamas Pharmaceuticals, Inc.4 EMD Serono3 Amarantus BioScience Holdings, Inc.1 Avanir Pharmaceuticals1 Great Lakes NeuroTechnologies Inc.1 University Health Network, Toronto1 University of Stellenbosch1

Trial status mix

COMPLETED11

UNKNOWN1

Phase mix

PHASE36

PHASE25

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.